54977-91-2

Usage

Uses

Used in Pharmaceutical Industry:
3-AMINO-N-BENZYL-BENZAMIDE is used as a key intermediate in the synthesis of pharmaceutical compounds for its potential therapeutic effects on certain diseases. Its unique structure allows for the development of new drugs with specific targeting and action mechanisms.
Used in Research and Development:
In the research industry, 3-AMINO-N-BENZYL-BENZAMIDE is employed as a reagent and building block for the creation of novel organic molecules. It aids scientists in exploring new chemical pathways and discovering innovative applications in medicine.
Used in Materials Science:
3-AMINO-N-BENZYL-BENZAMIDE is utilized as a component in the development of advanced materials with specific properties. Its integration into material compositions can lead to enhancements in areas such as drug delivery systems, sensors, or other specialized applications within the field of materials science.
Overall, 3-AMINO-N-BENZYL-BENZAMIDE's versatility and potential make it an essential compound in the ongoing pursuit of advancements in healthcare and material technologies.

InChI:InChI=1/C14H14N2O/c15-13-8-4-7-12(9-13)14(17)16-10-11-5-2-1-3-6-11/h1-9H,10,15H2,(H,16,17)

Upstream product

• 99-05-8 meta-aminobenzoic acid 
• 100-46-9 benzylamine 
• 874337-74-3 C₁₉H₂₂N₂O₃ 
• 121-92-6 3-nitrobenzoic acid 
• 7595-68-8 N-benzyl-3-nitrobenzamide 
• 3173-56-6 benzyl isothiocyanate 
• 121-90-4 m-nitrobenzoic acid chloride 
• 111331-82-9 3-[(tert-butoxycarbonyl)amino]benzoic acid 

Downstream Products

• 874337-77-6 diethyl ({[3-(benzylaminocarbonyl)phenyl]amino}methylene)malonate 
• 874337-81-2 ethyl 7-[(benzylamino)carbonyl]-4-oxo-1,4-dihydroquinoline-3-carboxylate 

Relevant academic research and scientific papers

A Practical and General Amidation Method from Isocyanates Enabled by Flow Technology

The addition of carbon nucleophiles to isocyanates represents a conceptually flexible and efficient approach to the preparation of amides. This general synthetic strategy has, however, been relatively underutilized owing to narrow substrate tolerance and the requirement for less favourable reaction conditions. Herein, we disclose a high-yielding, mass-efficient, and scalable method with appreciable functional group tolerance for the formation of amides by reaction of Grignard reagents with isocyanates. Through the application of flow chemistry and the use of substoichiometric amounts of CuBr2, this process has been developed to encompass a broad range of substrates, including reactants found to be incompatible with previously published procedures.

Synthesis and anion recognition studies of new ureylbenzamide-based receptors

A new group of ureylbenzamide-based receptors (1–4) has been synthesized; its binding affinity and capacity to form supramolecular complexes in solution with different anions have been investigated. For designing these receptors, it was considered a combination of the positions of the urea and amide groups (ortho and meta), and the chromophore groups naphthyl and nitrophenyl, yielding four receptors. The position and chromophore structure affected the acidity of the urea and amide hydrogens in the order 4>3>2>1. All the spectroscopic studies showed a significant change of 1 and 2 compared with 3 and 4 in the presence of different TBAX salts in acetonitrile. The 1H-NMR spectra show a preferential interaction of the anions with the urea group in receptors 1 and 2 due to the less steric hindrance, while there is a cooperative interaction of amide group in receptors 3 and 4 due to the closeness of both groups.

Design, Synthesis, and Evaluation of the Highly Selective and Potent G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure

A novel class of therapeutic drug candidates for heart failure, highly potent and selective GRK2 inhibitors, exhibit potentiation of β-adrenergic signaling in vitro studies. Hydrazone derivative 5 and 1,2,4-triazole derivative 24a were identified as hit compounds by HTS. New scaffold generation and SAR studies of all parts resulted in a 4-methyl-1,2,4-triazole derivative with an N-benzylcarboxamide moiety with highly potent activity toward GRK2 and selectivity over other kinases. In terms of subtype selectivity, these compounds showed enough selectivity against GRK1, 5, 6, and 7 with almost equipotent inhibition to GRK3. Our medicinal chemistry efforts led to the discovery of 115h (GRK2 IC50 = 18 nM), which was obtained the cocrystal structure with human GRK2 and an inhibitor of GRK2 that potentiates β-adrenergic receptor (βAR)-mediated cAMP accumulation and prevents internalization of βARs in β2AR-expressing HEK293 cells treated with isoproterenol. Therefore, 115h appears to be a novel class of therapeutic for heart failure treatment.

Design, synthesis and evaluation of benzoisothiazolones as selective inhibitors of PHOSPHO1

We report the discovery and characterization of a series of benzoisothiazolone inhibitors of PHOSPHO1, a newly identified soluble phosphatase implicated in skeletal mineralization and soft tissue ossification abnormalities. High-throughput screening (HTS)

The inhibition of factor inhibiting hypoxia-inducible factor (FIH) by β-oxocarboxylic acids

Cyclic β-oxocarboxylic acids inhibit factor inhibiting hypoxia-inducible factor via ligation to the active site iron. The Royal Society of Chemistry 2005.

The reduction of aromatic nitro groups on solid supports using sodium hydrosulfite (Na2S2O4)

An improved method for reducing aromatic nitro compounds on solid-phase supports using sodium hydrosulfite is presented. Conditions have been optimized to enable the use of this reagent for reductions on both polyethyleneglycol-polystyrene (PEG) resins an

GUANIDINE DERIVATIVES USEFUL IN THERAPY

Guanidine derivatives of formulanidine derivatives of formula I, wherein R8 represents hydrogen, halogen, alkyl C1 to 6, nitro, trifluoromethyl, thioalkyl C1 to 6, hydroxy, alkoxy C1 to 6, or a group selected from NR4R5, -O(CH2)pQ, -(CH2)mOQ, -(CH2)mNR1R2, -O(CH2)mNR1R2, -NHCO(CH2)mNH(CH2)nQ or -(CH2)pCONR1R2, or R8 represents the group A-CO-B; R9 represents hydrogen, halogen, alkyl C1 to 6, nitro or trifluoromethyl; and R1, R2, R4, R5, n, m, p, Q, A, B, and W are as defined in the specification, are described together with processes for their manufacture and compositions containing them. Compounds of formula I are useful in therapy

Potential Central Nervous System Active Agents. 1. Synthesis of Aromatic N-Benzyl Amides

The preparation and spectral properties (IR, MS, NMR) are given for 18 aromatic N-benzyl amides, variously substituted on the acyl part, including four new ones and an (E)-cinnamide derivative.The amides were prepared by heating the appropriate N-benzylammonium salt in o-xylene, or from the reaction of the corresponding acid chloride with benzylamine.The occurrence of an intense peak in their mass spectra, which corresponds to the loss of the N-acyl substituent without hydrogen transfer, is reported.